These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 304546)

  • 1. Immunosuppressive effect of serum in patients with ovarian carcinoma.
    Ueda K; Toyokawa M; Nakamori H; Sako H; Umesaki N; Nakade J; Lee T; Sugawa T
    Obstet Gynecol; 1978 Feb; 51(2):225-8. PubMed ID: 304546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of serum immunosuppressive effect in patients with ovarian cancer.
    Ueda K; Toyokawa M; Nakamori H; Sako H; Umesaki N; Nakade J; Lee T; Sugawa T
    Obstet Gynecol; 1979 Apr; 53(4):480-3. PubMed ID: 440651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
    Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
    Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
    Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
    Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
    Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. II. Immunodepressive effect of sera from bladder carcinoma.
    Nishio S; Horii A; Morikawa Y; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
    Invest Urol; 1979 Mar; 16(5):342-5. PubMed ID: 429128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.
    Macciò A; Lai P; Santona MC; Pagliara L; Melis GB; Mantovani G
    Gynecol Oncol; 1998 Jun; 69(3):248-52. PubMed ID: 9648596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of peripheral blood and ovarian cancer-infiltrating lymphocytes: effect of HIV infection on phenotypic expression and proliferative response.
    Guidozzi F; Reddy S; Wadee A
    Gynecol Oncol; 1994 May; 53(2):251-5. PubMed ID: 8188090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social support, psychological distress, and natural killer cell activity in ovarian cancer.
    Lutgendorf SK; Sood AK; Anderson B; McGinn S; Maiseri H; Dao M; Sorosky JI; De Geest K; Ritchie J; Lubaroff DM
    J Clin Oncol; 2005 Oct; 23(28):7105-13. PubMed ID: 16192594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between soluble Fas level and apoptosis of T cells in ovarian carcinoma.
    Ma Y; Ye F; Lv W; Cheng Q; Chen H; Xie X
    Eur J Obstet Gynecol Reprod Biol; 2008 Jun; 138(2):204-11. PubMed ID: 17826886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue.
    Hassan MI; Kassim SK; Saeda L; Laban M; Khalifa A
    Anticancer Res; 1999; 19(6C):5657-62. PubMed ID: 10697636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
    Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
    Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated (HLA-DR+) T-lymphocyte subsets in early epithelial ovarian cancer and malignant ovarian germ cell tumors.
    Miyazaki K; Shimada K; Katabuchi H; Arakane F; Arao S; Okamura H
    Gynecol Oncol; 1995 Sep; 58(3):362-7. PubMed ID: 7672702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
    Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cell-mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro.
    Pattillo RA; Story MT; Ruckert AC
    Cancer Res; 1979 Apr; 39(4):1185-92. PubMed ID: 421202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.